Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J S Rustin

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2011
Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performedG J S Rustin
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|June 20, 2007
The role of CA 125 in epithelial ovarian carcinomaH Mandeville, G J S Rustin
British Journal of Cancer|April 20, 2006
Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumoursC Ackers, G J S Rustin
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?G J S Rustin, M R Hall
The Oncologist|October 29, 2002
CA125 response: can it replace the traditional response criteria in ovarian cancer?A E Guppy, G J S Rustin
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 7, 2005
Vascular disrupting agents: a new class of drug in cancer therapyA M Gaya, G J S Rustin
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 27, 2007
Vascular damaging agentsD M Patterson, G J S Rustin
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 10, 2005
Epithelial ovarian cancer: a review of current managementA E Guppy, P D Nathan, G J S Rustin
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 14, 2004
Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal populationH E Lambert, W M Gregory, A E Nelstrop, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 1, 2007
A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sitesD M Patterson, N Murugaesu, L Holden, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2011
Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performedG J S Rustin
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|June 20, 2007
The role of CA 125 in epithelial ovarian carcinomaH Mandeville, G J S Rustin
British Journal of Cancer|April 20, 2006
Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumoursC Ackers, G J S Rustin
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?G J S Rustin, M R Hall
The Oncologist|October 29, 2002
CA125 response: can it replace the traditional response criteria in ovarian cancer?A E Guppy, G J S Rustin
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 7, 2005
Vascular disrupting agents: a new class of drug in cancer therapyA M Gaya, G J S Rustin
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 27, 2007
Vascular damaging agentsD M Patterson, G J S Rustin
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 10, 2005
Epithelial ovarian cancer: a review of current managementA E Guppy, P D Nathan, G J S Rustin
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 14, 2004
Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal populationH E Lambert, W M Gregory, A E Nelstrop, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 1, 2007
A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sitesD M Patterson, N Murugaesu, L Holden, et al.
Pageof 3